Comparison 3. Number of withdrawals due to adverse events.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Withdrawals due to adverse events over 6 months	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Fingolimod 0.5 mg versus placebo	1	114	Risk Ratio (M‐H, Random, 95% CI)	2.0 [0.53, 7.61]
1.2 Fingolimod 0.5 mg versus DMDs	1	1028	Risk Ratio (M‐H, Random, 95% CI)	3.21 [1.16, 8.86]
1.3 Fingolimod 1.25 mg versus placebo	2	298	Risk Ratio (M‐H, Random, 95% CI)	1.60 [0.63, 4.03]
1.4 Fingolimod 5.0 mg versus placebo	1	187	Risk Ratio (M‐H, Random, 95% CI)	1.98 [0.62, 6.35]
2 Withdrawals due to adverse events over 12 months	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Fingolimod 0.5 mg versus interferon beta‐1a	1	860	Risk Ratio (M‐H, Random, 95% CI)	1.51 [0.81, 2.80]
2.2 Fingolimod 1.25 mg versus interferon beta‐1a	1	851	Risk Ratio (M‐H, Random, 95% CI)	2.69 [1.54, 4.72]
3 Withdrawals due to adverse events over 24 months	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Fingolimod 0.5 mg versus placebo	2	1556	Risk Ratio (M‐H, Random, 95% CI)	1.42 [0.89, 2.25]
3.2 Fingolimod 1.25 mg versus placebo	2	1572	Risk Ratio (M‐H, Random, 95% CI)	1.93 [1.48, 2.52]
4 Withdrawals due to serious adverse events over 6 months	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 Fingolimod 0.5 mg versus placebo	1	114	Risk Ratio (M‐H, Random, 95% CI)	1.67 [0.42, 6.65]
4.2 Fingolimod 0.5 mg versus DMDs	1	1028	Risk Ratio (M‐H, Random, 95% CI)	2.71 [0.83, 8.88]
4.3 Fingolimod 1.25 mg versus placebo	2	298	Risk Ratio (M‐H, Random, 95% CI)	2.36 [0.99, 5.66]
4.4 Fingolimod 5.0 mg versus placebo	1	187	Risk Ratio (M‐H, Random, 95% CI)	2.77 [1.04, 7.38]
5 Withdrawals due to serious adverse events over 12 months	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 Fingolimod 0.5 mg versus interferon beta‐1a	1	860	Risk Ratio (M‐H, Random, 95% CI)	1.21 [0.72, 2.02]
5.2 Fingolimod 1.25 mg versus interferon beta‐1a	1	851	Risk Ratio (M‐H, Random, 95% CI)	1.85 [1.15, 2.96]
6 Withdrawals due to serious adverse events over 24 months	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 Fingolimod 0.5 mg versus placebo	2	1556	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.55, 1.50]
6.2 Fingolimod 1.25 mg versus placebo	2	1572	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.74, 1.29]